Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Eng
F C S
FC
Department of Surgical Oncology, University Health Network/Princess Margaret Hospital, University of Toronto, Toronto, Canada.
Easson
A M
AM
Szentgyorgyi
E
E
Knox
J J
JJ
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D003108:Colonic Diseases / Q000175:diagnosis / Q000209:etiology*; D003113:Colonoscopy; D003937:Diagnosis, Differential; D005500:Follow-Up Studies; D006801:Humans; D007416:Intestinal Perforation / Q000175:diagnosis / Q000209:etiology*; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D009392:Nephrectomy / Q000009:adverse effects*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011183:Postoperative Complications; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor; D012422:Rupture, Spontaneous; D000077157:Sorafenib; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D040262:Receptors, Vascular Endothelial Growth Factor